# A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

> **NCT06049667** · PHASE1 · RECRUITING · sponsor: **Nanjing Chia-tai Tianqing Pharmaceutical** · enrollment: 72 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** NTQ2494 tablet

## Key facts

- **NCT ID:** NCT06049667
- **Lead sponsor:** Nanjing Chia-tai Tianqing Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-07
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06049667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06049667, "A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06049667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*